ClinicalTrials.gg
RecruitingNCT05880628Updated Mar 12, 2024

Evaluation of Faisability, Safety and Effectiveness and of Discogel in Patients With Aneurysmal and Simple Bone Cysts

An observational study in Bone Cysts, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 6 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
30
Sex
All
01

Study summary

There is no consensus in the scientific literature for the treatment of aneurysmal and simple bone cysts. Some scientific articles with utilisation of sclerosis agents for the treatment of aneurysmal bone cysts: Ethibloc no longer marketed, pure Ethanol, Aetoxisclerol.

Read the detailed description

The aim of this work is therefore the evaluation of Discogel® in the treatment of Discogel®, which appears to be a safe and efficacity of method.

02

Conditions studied

  • Bone Cysts

Browse trials for

Keywords

  • Bone Cysts
  • Aneurysmal Bone Cysts
  • simple Bone Cysts
  • Discogel
  • Effectiveness
  • Safety
03

In context

Bone Cysts

18 studies on the registry are indexed under Bone Cysts; 5 are open to participants now.

Browse Bone Cysts studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 597 studies on the registry; 127 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel

Exclusion criteria

Exclusion Criteria:

  • Refusal
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Any patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel®

    Any patient with aneurysmal or simple bone cyst who benefit a sclerotherapy by Discogel® will be included. Analysis datas of medical record.

    Other: datas of medical record.

Interventions

  • Otherdatas of medical record.

    Analysis datas of medical record: * Feasibility of the technique * Safety of the technique * Efficacity (sclerose of the lesion)

06

What researchers measure

Primary outcomes

  1. Feasibility of the technique

    Collect from medical records the number of procedures that were completed and performed as theoretically intended.

    Time frame: Year: 2

Secondary outcomes

  1. Safety of the technique by number of adverse event

    collect in the medical record

    Time frame: Year: 2

  2. Number of discogel® injections by sclerose of the lesion

    Efficacity of the technique

    Time frame: Year: 2

07

Study locations

1 of 1 sites recruiting
  • CHU Saint-Etienne
    Saint-Étienne, France
    Recruiting
    • Sylvain Grange, MD · Principal investigator
    • Valentin Gineys, resident · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05880628
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Apr 14, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 12, 2024

Study contacts

Sylvain Grange, MD
Contact
Sylvain.Grange@chu-st-etienne.fr
(0)477829066 ext. +33
Valentin Gineys, resident
Contact
Sylvain.Grange@chu-st-etienne.fr
(0)477829066 ext. +33
Sylvain Grange, MD
principal investigator · CHU Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion